FIH Phase I dose escalation and expansion study of anti-HER2 ADC MRG002 in patients with HER2 positive solid tumors

Presentation Number 271P

Ye Guo¹, Junli Xue¹, Wei Peng¹, Liqiong Xue¹, Xiaoxiao Ge¹, Wei Zhao¹, Wenbo Tang¹, Weiqi Nian², Qun Li¹, Sihui Zhang³, Jinghui Sun³, Maggie Li³, Chaohong Hu³, Jin Li¹; ¹Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China; ²Chongqing Cancer Hospital ;³Shanghai Miracogen Inc., Shanghai, China

BACKGROUND

MRG002 is an antibody-drug conjugate(ADC) composed of a humanized anti-HER2 monoclonal antibody conjugated to monomethyl auristatin E (MMAE), via a valine-citrulline (vc) linker. MRG002 is presently being investigated as monotherapy in an ongoing Phase I study for safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity in patients (pts) with HER2 positive advanced or metastatic solid tumors.

OBJECTIVE

Primary Objectives

- Phase Ia: To identify Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D)
- Phase Ib: safety and tolerability

Secondary Objectives

- Phase Ia: Pharmacokinetic (PK), immunogenicity (ADA), antitumor activity
- Phase Ib: antitumor activity, PK, ADA

Exploratory Objectives

 Assess HER2 expression and amplification level in tumor specimens and correlation with efficacy indicators of tumor response

METHODS

KEY Eligibility Criteria

1.Expected survival time ≥ 12 weeks;

2.Patients with histologically and/or cytologically confirmed HER2-positive solid tumors who have failed standard therapy or for whom no standard therapy exists or standard therapy is not appropriate;

3.Patients must have at least one evaluable lesion (Phase Ia) or measurable lesion (Phase Ib) according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1);

4.Score of ECOG for performance status is 0 or 1;

5.Prior anti-tumor treatment-related AEs (NCI CTCAE v5.0 Criteria) have recovered to \leq Grade 1 (except alopecia);

6.No severe cardiac dysfunction with left ventricular ejection fraction (LVEF) \geq 50%;

- 7.Organ functions must meet the basic requirements;
- 8. Coagulation function must meet the basic requirements;

9.Cumulative anthracycline dose \leq 360 mg/m² doxorubicin or its equivalent, 720 mg/m² epirubicin.

RESULTS

In Phase Ia dose escalation utilizing a "3+3" design to identify MTD/RP2D (Figure1), a total of 25 pts with breast cancer (BC) (n=19), salivary gland cancer (SGC) (n=3), gastric cancer (GC) (n=2), and colorectal cancer (CRC) (n=1) were enrolled to identify MTD/RP2D. The starting dose of MRG002 was 0.3 mg/kg, followed by 0.6, 1.2, 1.8, 2.2, 2.6, and 3.0 mg/kg, and all pts with BC and GC were HER2 positive per CAP guidelines. For the other tumor types, pts were IHC 2+ or 3+, regardless of HER2 FISH status. Enrolled pts received MRG002 every three weeks (Q3W) for a maximum of 8 cycles.

Figure 1. Phase la dose escalation								
0.3 mgkg N=1 0.6 1.2 mg/kg mg/kg N=3 0.6 1.2 mg/kg N=3 0.6 N=6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.								
1 SGC patient in 1.8mg/kg, 1 SGC patient and 1GC patient in 2.2 mg/kg,1CRC patient in 2.6 mg/kg, 1 GC patient and 1SGC in 3.0 mg/kg.								

,									
Table 1. Patient demographics and baseline characteristics									
Characteristic	Patients (N = 25)								
Age									
Median (range) — years	53 (33–66)								
Sex									
Males, n (%)	5 (20)								
Females, n (%)	20 (50)								
ECOG performance -status score , n (%)									
1	25 (100)								
The median number of prior therapies	5 (1, 11)								

The median age was 53 (30, 66) years. The median number of prior therapies was 5 (1,11) (Table 1). Among 22 pts who had at least one tumor assessment, 10 PR (45%), 8 SD (36%) .The investigator assessed ORR was 45% and the DCR was 82%. Of these 22 pts, 17 pts were breast cancer, 9 PR, 4 SD, and ORR was 53% (9/17). DCR was 76% (13/17) (Figure 2-3).

The terminal elimination half-life (T_{1/2}) of MRG002 was approximately 2 days at 2.6 mg/kg.

Commonly observed treatment-emergent adverse events (TRAEs) were neutrophil count decreased (56%), aspartate aminotransferase (AST) increased (56%), white blood cell (WBC) decreased (56%), lactate dehydrogenase increased (44%), alopecia (44%), creatine phosphokinase (CPK) increased (40%), alanine aminotransferase (ALT) increased (36%), triglyceride increased (32%), cholesterol increased (32%), gamma-glutamyl transpeptidase(GGT) increased (32%), appetite decreased (32%), and hypoaesthesia (32%). Majority of AEs were mild to moderate in severity. The most commonly reported TRAEs \geq Grade 3 were neutrophil count decreased and triglycerides increased in 3 pts (12%), respectively. The treatment-related Serious Adverse Events (SAEs) were reported in 6 pts (24%) including GGT increased, AST/ALT increased, neutrophil count decreased, LEVF decreased, fatigue, peripheral neuropathy.

There were 4 Dose-limiting toxicities events (DLTs) occurred in the dose escalation phase, including 1 DLT (Grade 3 AST/ALT increased) at 2.2 mg/kg, 1 DLT (Grade 3 GGT increased) at 2.6 mg/kg, and 2 DLTs (1 Grade 3 CPK increased and 1 Grade 3 LVEF decreased) at the maximum administered dose level of 3.0 mg/kg, and MTD/RP2D was determined to be 2.6 mg/kg (**Table 3**).




Table 3. Safety Summary

		Dose Cohort (mg/kg)											Total	
Adverse Events ^ª		0.3				1.2 1.8		2.2		2.6	3.0		(n=25)	
		(n=1	· /	()		1)	(n=3)	(n=7)		(n=6)	(n=6	/	,	
		n (%				6)	n (%)	n (%)		n (%)		n (%) n (%)		
Total Patients with AEs		1 (10	.,	1 (100)	1 (10		3 (100)		100)	6 (100)				
		1 (10		1 (100)	,		3 (100)		100)	6 (100)		.,	25 (100)	
≥ Grade 3		1 (100)		0			3 (100)		(29)	3 (50)	5 (83)	14 (56)	
Death		0		0			0	0		0	0		0	
SAEs		0		0	0 0		2 (67)	2 (67) 3 (43		1 (17)	1 (17)	7 (28)	
Treatmen		0		0			1 (33)	1 (14)		1 (17)	1 (17	n	4 (16)	
Discontinua						0 1 (33)		1 (14)			. (17	,	+(10)	
Patients with MRG002 Related AEs ^b		1 (10	0)	1 (100)	1 (10	00)	3 (100)	7 (100)		6 (100) 6 (10		0) 25 (100)		
Grade 1-			0)	0) 1 (100) 1		00)	3 (100)	7 (100)		6 (100)	6 (10	D) :	25 (100)	
≥ Grade 3	Grade 3		0)	O Ó	Ò		3 (100)	2	(29)	3 (50)	5 (83	(83) 14 (56)		
Death		0	0		Ō		0	0		0 0		0		
SAEs				0	0		2 (67)	2	(29)	1 (17)	(17) 1 (17)		6 (24)	
Treatment Discontinuation		0		0	0		1 (33)	1 (14)		1 (17)	1 (17)	4 (16)	
Common TRAEs (PT) ≥ 30%	Total (n = 25 (100		≥G3	3 TRAEs ≥ 10	0%	(6 (24%)	DLT	Event	s				
Neutrophil count decreased	14 (56)	Neut	Neutrophil count decreased			3 (12)	Dose	Patient	Preferred		CTCAF	CTCAE	
AST increased	14 (56)						Cohort (ma/ka)	ID	Term	Action Taken		Grade Causality	
WBC decreased	14 (14 (56)		Triglycerides increased		3 (12)		(Blood	Treatment no			
Lactate dehydrogenase increased	11 (44)	Trea	tment-related S	SAEs	6	6 (24%)	1.8	E01006*	triglycerides increased	change	3	3 Possibly related	
Alopecia	11 (4	44)	GGT increased			1 (4)		2.2	E01007	AST/ALT	Study	3	3 Possibly	
CPK increased	10 (40)	AST/ALT increased			1 (4)				increased	discontinuation		5 related	
ALT increased	9 (3	86)	No. of the second s			1 (4)		2.6	E01014	GGT increased	Study	3	Definitely	
Triglyceride increased	8 (3	32)	Neut	Neutrophil count decreased							discontinuation		3 related	
Cholesterol increased	8 (3	32)	LEVF decreased			1 (4)			E01020	Creatine kinase increased	Treatment no	3	Possibly	
GGT increased	8 (3	32)	Fatique			1 (4)		3.0			change	5	related	
Appetite decreased	8 (3	32)						5.0	F06002	LEVF	Study	3	Possibly	
Hypoaesthesia	8 (32)		Peripheral neuropathy				1 (4)		200002	decreased	discontinuation	3	3 related	

^a All AEs reported from the time of first dose of MRG002 in first patient to the date of cutoff (26 Aug 2021).
^b Investigator assessment of relatedness.

* DLT exception approved by Ethics Committee.

Based on Common Terminology Criteria for Adverse Events(CTCAE) Version 5.0

CONCLUSIONS

The dose escalation of MRG002 showed manageable safety profile and encouraging antitumor activity in pts with HER2 positive solid tumors including BC, GC and other tumor types, the MTD/RP2D was determined to be 2.6 mg/kg. MRG002 is currently being investigated in Phase Ib dose expansion and exploratory Phase II studies.

Acknowledgments:

Shanghai Miracogen Inc. and authors thank all the investigators and patients who participated in this clinical study.

Disclosure:

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Clinical Trail Number: NCT04941339; E-mail Address: pattrickguo@gmail.com